3/18
04:38 pm
ibrx
ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer [Yahoo! Finance]
Low
Report
ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer [Yahoo! Finance]
3/18
06:35 am
ibrx
ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference [Yahoo! Finance]
Medium
Report
ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference [Yahoo! Finance]
3/17
04:42 pm
ibrx
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion [Seeking Alpha]
Medium
Report
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion [Seeking Alpha]
3/17
02:07 pm
ibrx
NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus [Yahoo! Finance]
Low
Report
NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus [Yahoo! Finance]
3/17
09:03 am
ibrx
ImmunityBio (IBRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
Medium
Report
ImmunityBio (IBRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
3/17
07:42 am
ibrx
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease [Yahoo! Finance]
Medium
Report
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease [Yahoo! Finance]
3/17
07:30 am
ibrx
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease
Low
Report
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease
3/16
07:47 pm
ibrx
IBRX Stock Jumps on Progress in NK Cell Therapy Production [Yahoo! Finance]
Low
Report
IBRX Stock Jumps on Progress in NK Cell Therapy Production [Yahoo! Finance]
3/15
10:06 pm
ibrx
Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now? [Yahoo! Finance]
Low
Report
Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now? [Yahoo! Finance]
3/14
06:58 am
ibrx
ImmunityBio (IBRX) was upgraded by BTIG Research to "strong-buy".
Low
Report
ImmunityBio (IBRX) was upgraded by BTIG Research to "strong-buy".
3/13
10:14 pm
ibrx
ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells' [Yahoo! Finance]
Low
Report
ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells' [Yahoo! Finance]
3/13
07:42 pm
ibrx
Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge [Yahoo! Finance]
Low
Report
Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge [Yahoo! Finance]
3/13
03:47 pm
ibrx
IBRX Stock: Anktiva's Approvals and What Comes Next [Yahoo! Finance]
Low
Report
IBRX Stock: Anktiva's Approvals and What Comes Next [Yahoo! Finance]
3/13
07:43 am
ibrx
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors [Yahoo! Finance]
Medium
Report
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors [Yahoo! Finance]
3/13
07:30 am
ibrx
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
Medium
Report
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
3/12
08:03 am
ibrx
ImmunityBio (IBRX) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.
Medium
Report
ImmunityBio (IBRX) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.
3/10
07:25 am
ibrx
Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) [Yahoo! Finance]
Medium
Report
Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) [Yahoo! Finance]
3/10
05:42 am
ibrx
FDA Review And Saudi Approval Keep ANKTIVA Central To ImmunityBio Story [Yahoo! Finance]
Medium
Report
FDA Review And Saudi Approval Keep ANKTIVA Central To ImmunityBio Story [Yahoo! Finance]
3/9
03:26 pm
ibrx
ImmunityBio (IBRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
Low
Report
ImmunityBio (IBRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
3/9
07:38 am
ibrx
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data [Yahoo! Finance]
Low
Report
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data [Yahoo! Finance]
3/9
07:30 am
ibrx
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
Low
Report
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
3/5
02:31 pm
ibrx
ImmunityBio Bladder Cancer Milestone Raises Questions On Global ANKTIVA Rollout [Yahoo! Finance]
Low
Report
ImmunityBio Bladder Cancer Milestone Raises Questions On Global ANKTIVA Rollout [Yahoo! Finance]
3/5
10:31 am
ibrx
Forget ImmunityBio: This Big-Cap Pharma Is the Safer Play on Next-Gen Cancer Therapies [Yahoo! Finance]
Low
Report
Forget ImmunityBio: This Big-Cap Pharma Is the Safer Play on Next-Gen Cancer Therapies [Yahoo! Finance]
3/5
09:43 am
ibrx
ImmunityBio (IBRX) Is Down 5.8% After ANKTIVA Rollout Fuels Revenue Jump And Narrower Losses [Yahoo! Finance]
Low
Report
ImmunityBio (IBRX) Is Down 5.8% After ANKTIVA Rollout Fuels Revenue Jump And Narrower Losses [Yahoo! Finance]
3/4
09:03 am
ibrx
ImmunityBio (IBRX) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $12.00 price target on the stock, up from $7.00.
Medium
Report
ImmunityBio (IBRX) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $12.00 price target on the stock, up from $7.00.